Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.